DSIP

Typical use cases

Dosing guidelines

Titration

No standardized titration exists. Community discussions describe beginning at a low single dose (around 100 mcg) and adjusting only by subjective response, given the absence of formal dose-finding data. Informational only, not a recommendation.

Reconstitution

Supplied as a lyophilized powder; reconstituted with bacteriostatic water. A commonly reported preparation is 1 mg powder in 1 mL bacteriostatic water (yielding ~100 mcg per 0.1 mL / 10 units on a U-100 insulin syringe). Water is typically added slowly down the vial wall, then swirled gently rather than shaken to avoid foaming.

Injection sites

Subcutaneous injection, typically into the abdomen with site rotation; subcutaneous administration is the most commonly reported route.

Storage & handling

Lyophilized powder stored frozen (around -20 C) for long-term; once reconstituted, refrigerated at 2-8 C and used within several days (commonly cited stability ~4 days / 96 hours). Avoid repeated freeze-thaw cycles and protect from light.

Side effects

• Injection-site irritation or redness Mild · Common
• Headache Mild · Uncommon
• Daytime grogginess or fatigue Mild · Uncommon
• Dizziness Mild · Rare
• Nausea Mild · Rare
• Transient changes in heart rate or palpitations (anecdotal) Moderate · Rare

Research summary

DSIP was first characterized by the Swiss Schoenenberger-Monnier group, who isolated a sleep-related factor from the cerebral venous blood of rabbits in the mid-1970s and named it for its capacity to induce delta (slow-wave) EEG activity. The peptide is unusual in that, despite decades of study, its endogenous receptor, gene, and precise mechanism remain unidentified, leading reviewers to describe it as a "still unresolved riddle" and to suggest that a DSIP-like peptide rather than DSIP itself may drive some observed effects. Preclinical animal work is the strongest part of its evidence base: studies report stress-protective and adaptogenic effects, modulation of the hypothalamic-pituitary-adrenal axis, anticonvulsant and antioxidant activity, and a role in sleep-related growth hormone release (anti-DSIP antiserum blocked the GH and slow-wave-sleep rebound after sleep deprivation in rats). Human data are limited and mixed: an early small double-blind trial reported subjective drowsiness and improved sleep onset/efficiency in healthy volunteers, but a later double-blind study in chronic insomniacs concluded the effects were weak and unlikely to be of major therapeutic benefit. A practical limitation is the peptide's very short reported plasma half-life (on the order of minutes, due to a specific aminopeptidase) and uncertainty about how reliably exogenous DSIP crosses the blood-brain barrier. Overall, DSIP remains an investigational, poorly characterized compound with no regulatory approval and no robust modern human clinical trials; reported community uses are extrapolations from older or animal data.

Key references

• https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
• https://pubmed.ncbi.nlm.nih.gov/16539679/
• https://pubmed.ncbi.nlm.nih.gov/6895513/
• https://pubmed.ncbi.nlm.nih.gov/1299794/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC280272/
• https://pubchem.ncbi.nlm.nih.gov/compound/68816

Related compounds